Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02606721
Other study ID # ORA-FA-001
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 2016
Est. completion date October 2016

Study information

Verified date May 2016
Source ORA, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The objective of this study is to correlate various diagnostic measurements taken during an escalating dose oral food challenge to the subject's response. This study will investigate whether non invasive objective biomarkers can indicate a positive response to an escalating dose OFC before a systemic reaction occurs.


Description:

Patients often discover their food allergies after consuming a given food and experiencing a subsequent allergic reaction. The majority of patients (75%) will then consult a food allergist for formal diagnosis and treatment information. With respect to patient quality of life, there is tremendous benefit in having a confirmed diagnosis of food allergy as often patients are unsure of the source of their reaction outside the office. Allergists will conduct a Skin Prick Test (SPT) and assess serum specific IgE levels to screen for specific food protein sensitivities. However, a positive response in SPT and specific IgE will confirm only sensitivity, and in more than 70% of cases patients that respond positively to SPT and specific IgE testing will NOT manifest an allergic response to food consumption. To address this issue, most food allergists will recommend an oral food challenge in a controlled setting to confirm the allergic response from consuming the suspected foods. The oral food challenge (OFC) consists of consuming escalating levels of the suspect food, (usually mixed in applesauce or controlled baked goods), until either a reaction manifests or until the challenge is complete with no reaction. The food challenge process poses significant risk to the patient. In 5% of cases, the patient experiences a severe allergic response which requires the use of epinephrine. These responses typically consist of severe reactions in GI or respiratory and arise from challenging patients with higher doses of food allergen then is necessary to prove a mild allergic response, which is directly linked to variability in diagnosis of a positive response, within subjects and within investigators.

The investigators hypothesize that measurements taken using minimally-invasive diagnostic tests during the course of an escalating-dose oral food challenge will be able to detect a positive response before a systemic reaction occurs in the patient and may be able to screen with individuals predisposed to EOE.


Recruitment information / eligibility

Status Completed
Enrollment 6
Est. completion date October 2016
Est. primary completion date September 2016
Accepts healthy volunteers No
Gender All
Age group 5 Years to 35 Years
Eligibility Inclusion Criteria:

- Male or female of any race, aged 5 - 35 years with planned clinical oral food challenge;

- Have provided verbal and written informed consent. If under the age of 18, a parent/guardian must provide verbal and written informed consent;

- Be willing and able to follow instructions, including participation in study assessments, and can be present for the required study visits for the duration of the study;

Exclusion Criteria:

- Be unable to comply with all study parameters and procedures

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Tufts Medical Center Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
ORA, Inc. Tufts Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Correlation between objective biomarker measures and challenge outcome Correlation between imaging measurements taken before, during, and after oral food challenge to outcome of challenge Change from baseline at 15 minute intervals until completion of challenge (approximately 3 hours)
Primary Correlation between subjective biomarker measures and challenge outcome Correlation between symptom questionnaire taken before, during, and after oral food challenge to outcome of challenge Change from baseline at 15 minute intervals until completion of challenge (approximately 3 hours)
See also
  Status Clinical Trial Phase
Completed NCT01904604 - Peanut Epicutaneous Phase II Immunotherapy Clinical Trial Phase 2
Enrolling by invitation NCT04885959 - The Effects of Traditional Asian Diet on Gut Microbiome and Metabolome in Healthy Volunteers and Pregnancy on Subsequent Infant's Allergy Development N/A
Recruiting NCT03974555 - Epidemiological Investigation and Cohort Study on Food Allergy in Children Aged 3 to 6 Years in Wenzhou and Taizhou Urban Areas
Recruiting NCT05177744 - Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
Completed NCT01420705 - Bacille Calmette-Guérin (BCG) Vaccine and Atopy N/A
Completed NCT00850668 - Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults Phase 1
Withdrawn NCT00736112 - Food Allergy - Tubes - Adenoids (FATA) Trial N/A
Active, not recruiting NCT00298337 - Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008 Phase 2/Phase 3
Completed NCT03693456 - Food Allergy Diagnostic Test Response to Previous Oral Challenge Response N/A
Completed NCT00461097 - Oral Immunotherapy for Childhood Egg Allergy Phase 2
Active, not recruiting NCT02457416 - Take Away Food Allergy; Inducing Tolerance in Children Allergic to Peanut N/A
Completed NCT02825069 - Study on the Induction of Food Tolerance in Babies N/A
Completed NCT02350660 - Oral Immunotherapy for Peanut and Mammalian Meat Allergies N/A
Completed NCT01084174 - A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy Phase 1/Phase 2
Completed NCT00597675 - Oral Immunotherapy for Peanut Allergy (PMIT) Phase 2
Completed NCT00932828 - Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study Phase 2
Completed NCT01373242 - Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance Phase 1/Phase 2
Completed NCT00578656 - An Interventional Study of Milk Allergy Phase 0
Completed NCT00356174 - An Observational Study of Childhood Food Allergy N/A
Completed NCT02304991 - FARE Peanut SLIT and Early Tolerance Induction Phase 2